Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective

Oncogenic mutations affecting members of the RAS gene family (NRAS, KRAS, HRAS) have been recurrently described in many solid tumors and hematological malignancies including multiple myeloma in a v...